Drug-induced dyskinesias.
Identifieur interne : 000B68 ( PubMed/Corpus ); précédent : 000B67; suivant : 000B69Drug-induced dyskinesias.
Auteurs : Philippe DamierSource :
- Current opinion in neurology [ 1473-6551 ] ; 2009.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiparkinson Agents.
- diagnostic imaging : Dyskinesia, Drug-Induced, Parkinson Disease.
- drug therapy : Parkinson Disease.
- physiopathology : Dyskinesia, Drug-Induced.
- prevention & control : Dyskinesia, Drug-Induced.
- Humans, Positron-Emission Tomography.
Abstract
Recent studies have improved our knowledge of the factors responsible for the development of dyskinesias in Parkinson's disease and the associated pathophysiology. Deep brain stimulation has been shown to be effective to treat severe tardive dyskinesias. This review highlights some recent findings related to levodopa-induced and antipsychotic-induced dyskinesias.
DOI: 10.1097/WCO.0b013e32832d9dc4
PubMed: 19491677
Links to Exploration step
pubmed:19491677Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug-induced dyskinesias.</title>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation><nlm:affiliation>CHU Nantes, CIC 04, Pôle neurosciences, Nantes, France. philippe.damier@chu-nantes.fr</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19491677</idno>
<idno type="pmid">19491677</idno>
<idno type="doi">10.1097/WCO.0b013e32832d9dc4</idno>
<idno type="wicri:Area/PubMed/Corpus">000B68</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B68</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Drug-induced dyskinesias.</title>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation><nlm:affiliation>CHU Nantes, CIC 04, Pôle neurosciences, Nantes, France. philippe.damier@chu-nantes.fr</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Current opinion in neurology</title>
<idno type="eISSN">1473-6551</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Dyskinesia, Drug-Induced (diagnostic imaging)</term>
<term>Dyskinesia, Drug-Induced (physiopathology)</term>
<term>Dyskinesia, Drug-Induced (prevention & control)</term>
<term>Humans</term>
<term>Parkinson Disease (diagnostic imaging)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Positron-Emission Tomography</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Positron-Emission Tomography</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent studies have improved our knowledge of the factors responsible for the development of dyskinesias in Parkinson's disease and the associated pathophysiology. Deep brain stimulation has been shown to be effective to treat severe tardive dyskinesias. This review highlights some recent findings related to levodopa-induced and antipsychotic-induced dyskinesias.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19491677</PMID>
<DateCreated><Year>2009</Year>
<Month>07</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted><Year>2009</Year>
<Month>09</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>11</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6551</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>22</Volume>
<Issue>4</Issue>
<PubDate><Year>2009</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Current opinion in neurology</Title>
<ISOAbbreviation>Curr. Opin. Neurol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Drug-induced dyskinesias.</ArticleTitle>
<Pagination><MedlinePgn>394-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/WCO.0b013e32832d9dc4</ELocationID>
<Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Recent studies have improved our knowledge of the factors responsible for the development of dyskinesias in Parkinson's disease and the associated pathophysiology. Deep brain stimulation has been shown to be effective to treat severe tardive dyskinesias. This review highlights some recent findings related to levodopa-induced and antipsychotic-induced dyskinesias.</AbstractText>
<AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">The reported advantage of using a dopamine agonist as an initial treatment to prevent the development of dyskinesias in Parkinson's disease appears to be less evident after a long-term follow-up. Other factors, related to the etiopathogenesis of Parkinson's disease or to patients' endophenotypes, are beginning to be identified. Several brain changes have been found to be associated with levodopa-induced dyskinesias. PET studies have evidenced an increased level of synaptic dopamine in the striatum. Neurophysiological studies have suggested that dyskinesias might reflect abnormal skill memorization processes within the cortico-subcortical loops. A dysfunction of the mechanisms trying to compensate for dopamine deficiency and its brain consequences could be responsible for these changes induced by the dopaminergic treatment. Bilateral pallidal stimulation has been shown to be an effective and safe treatment for severe tardive dyskinesias.</AbstractText>
<AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">These findings will improve future strategies to prevent and treat Parkinson's disease dyskinesias and offer a much needed treatment for severe tardive dyskinesias.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Damier</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>CHU Nantes, CIC 04, Pôle neurosciences, Nantes, France. philippe.damier@chu-nantes.fr</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Curr Opin Neurol</MedlineTA>
<NlmUniqueID>9319162</NlmUniqueID>
<ISSNLinking>1350-7540</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>46</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>6</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>6</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>9</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19491677</ArticleId>
<ArticleId IdType="doi">10.1097/WCO.0b013e32832d9dc4</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000B68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:19491677 |texte= Drug-induced dyskinesias. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19491677" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |